New drug moxidectin put to the test against river blindness in massive safety trial

NCT ID NCT04311671

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large Phase 3 trial compared the safety of a single dose of moxidectin versus ivermectin in nearly 13,000 people living in areas where river blindness is common. Some participants also received albendazole for lymphatic filariasis. The goal was to see if moxidectin causes fewer or less severe side effects. Results will help determine if moxidectin can be a safer alternative for controlling this parasitic disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
moxidectin (compared to ivermectin, with or without albendazole)
What this could lead to
If moxidectin proves safer, it could become a new treatment option for river blindness, potentially reducing side effects in affected communities.
What could go wrong
This trial only measures safety, not effectiveness. Even if safe, moxidectin may not work better than existing treatments. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire

    Abidjan, Côte d’Ivoire

  • Centre de Recherche pour les Maladies Tropicales Negligees

    Rethy, Ituri, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.